lncRNA MSC-AS1 Aggravates Diabetic Nephropathy by Regulating the miR-325/CCNG1 Axis | Zendy

Hongtu Zhao | Zendy; Yuanyuan Cui | Zendy; Fuqing Dong | Zendy; Wencong Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

lncRNA MSC-AS1 Aggravates Diabetic Nephropathy by Regulating the miR-325/CCNG1 Axis

Author(s) -

Hongtu Zhao,

Yuanyuan Cui,

Fuqing Dong,

Wencong Li

Publication year - 2022

Publication title -

journal of healthcare engineering

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.509

H-Index - 29

eISSN - 2040-2309

pISSN - 2040-2295

DOI - 10.1155/2022/2279072

Subject(s) - downregulation and upregulation , gene knockdown , flow cytometry , diabetic nephropathy , cancer research , cyclin d1 , chemistry , biology , apoptosis , kidney , microbiology and biotechnology , endocrinology , cell cycle , gene , biochemistry

Background. Diabetic nephropathy (DN) is the most common microvascular complication of diabetes and has become the second leading cause of end-stage renal disease in the world. This study aims to clarify the regulatory mechanism of the lncRNA MSC-AS1/miR-325/cyclin G1 (CCNG1) axis in DN. Methods. The regulatory mechanism of lncRNA MSC-AS1/miR-325/CCNG1 was evaluated by RT-qPCR, CCK-8 assay, flow cytometry assay, RNA pull-down assay, ELISA, and western blot assay. Results. Upregulation of lncRNA MSC-AS1 was detected in DN patients and HRMC cells treated with high glucose (HG). Knockdown of lncRNA MSC-AS1 reduced the proliferation, fibrosis, and inflammation of HRMC cells induced by HG. In addition, lncRNA MSC-AS1 acts as a miR-325 sponge in the DN. CCNG1 is the direct target of miR-325, which can be positively regulated by lncRNA MSC-AS1 in DN. More importantly, downregulation of miR-325 and upregulation of CCNG1 can attenuate the protective effect of lncRNA MSC-AS1 knockdown on DN. Conclusion. lncRNA MSC-AS1 aggravates DN by downregulating miR-325 and upregulating CCNG1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research